

Attorney Docket No.: 5638.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed July 1, 2004.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from October 1, 2004 to January 1, 2005. The required fee for the extension is estimated to be \$1,020.

The fee for claims has been calculated as shown below:

Total: $113 - 112 = 1 \times 50 = \50

Independent: $2 - 4 = 0 \times 200 = \$0$

Total additional fee for claims required is \$50.


Please charge the required extension and claims fees, estimated to be \$1,070, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 22, 2004

01/11/2005 GTRAHNEL 00000002 501701 10038723

01 FC:1253 1020.00 DA
02 FC:1202 50.00 DA


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

*Fee Purpose
only*

Attorney Docket No.: 5638.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

*Fee Purpose
only*TERMINAL DISCLAIMER TO OBVIATE A
DOUBLE PATENTING REJECTION OVER A PRIOR PATENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney or agent of record for the instant application.

Novozymes A/S, the owner of the entire interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 6,352,851. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer.


01/11/2005 GTRAKEL 00000003 501701 10038723

01 FC:1814 130.00 DA

Please charge the required fee, estimated to be \$110.00, to Novozymes North America, Inc. Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 22, 2004



Jason J. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

- 2 -